ClinicalTrials.gg
Active, not recruitingNCT06246513EMERGENEUpdated Mar 2, 2026

A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4

A Phase 3 interventional study of SRP-9003 and Glucocorticoid in Limb-girdle Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Active, not recruiting at 10 sites in 6 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Sarepta Therapeutics, Inc. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States — 3 open to participants now, 9 under way, 1 of them phase 3. Muscular Dystrophies, Limb-Girdle · United States.

Enrollment
6th of 17
17 · median 11
Started
2024
with 1 other
Phase 3
3 of 30
none open now
Registered
28th of 30
by date
Lead sponsor
8 of 30
Sarepta Therapeutics, Inc.

Among the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States, this one is the 6th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 in phase 3, and was the 28th registered.

Muscular Dystrophies, Limb-Girdle

47 studies on the registry are indexed under Muscular Dystrophies, Limb-Girdle; 10 are open to participants now.

Browse Muscular Dystrophies, Limb-Girdle studies →

Open to participants now

3 of the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Muscular Dystrophies, Limb-Girdle studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, global study of the effects of a single systemic dose of SRP-9003 on beta-sarcoglycan (β-SG) gene expression in participants with limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4). This study will consist of both ambulatory participants (Cohort 1) and non-ambulatory participants (Cohort 2).

03

Conditions studied

  • Limb-girdle Muscular Dystrophy

Keywords

  • Limb Girdle Muscular Dystrophy Type 2E/R4
  • LGMD2E/R4
  • Pediatric
  • SRP-9003
  • scAAVrh74.MHCK7.hSGCB
  • bidridistrogene xeboparvovec
  • Non-ambulatory
  • Ambulatory
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cohort 1, only ambulatory participants:

    • Able to walk without assistive aid
    • 10MWR \<30 seconds
    • NSAD ≥25
  • Cohort 2, only non-ambulatory participants:

    • 10MWR ≥30 seconds or unable to perform
    • PUL 2.0 entry scale score ≥3
  • Participants must possess 1 homozygous or 2 heterozygous pathogenic and/or likely pathogenic β-SG DNA gene mutations
  • Able to cooperate with muscle testing
  • Participants must have adeno-associated virus serotype rh74 (AAVrh74) antibody titers \<1:400 (that is, not elevated) as determined by AAVrh74 antibody enzyme-linked immunosorbent assay.

Exclusion criteria

Exclusion Criteria:

  • \< 40% or clinical signs and/or symptoms of cardiomyopathy
  • Forced vital capacity ≤40% of predicted value and/or requirement for nocturnal ventilation
  • Diagnosis of (or ongoing treatment for) an disease and on active treatment
  • Presence of any other illness or medical condition (other than LGMD2E/R4)

Other inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    SRP-9003

    Participants will receive a single intravenous (IV) infusion of SRP-9003.

    Biological: SRP-9003 · Drug: Glucocorticoid

Interventions

  • BiologicalSRP-9003

    Solution for single IV infusion

    Also known as: scAAVrh74.MHCK7.hSGCB, bidridistrogene xeboparvovec

  • Oral tablet (prophylactic)

    Also known as: Prednisone or equivalent

06

What researchers measure

Primary outcomes

  1. Cohort 1: Change from Baseline in β-SG Expression at Day 60 Post-dose as Measured by Immunofluorescence (IF) Percent β-SG Positive Fibers

    Time frame: Baseline, Day 60

Secondary outcomes

  1. Cohort 1 and Cohort 2: Change From Baseline in β-SG Expression at Day 60 Post-dose as Measured by Western Assay

    Time frame: Baseline, Day 60

  2. Cohort 1 and Cohort 2: Change From Baseline in β-SG Expression at Day 60 Post-dose as Measured by IF Percent Fluorescent Intensity (PFI)

    Time frame: Baseline, Day 60

  3. Cohort 2: Change From Baseline in β-SG Expression at Day 60 Post-dose as Measured by IF Percent β-SG Positive Fibers (PβSGPF)

    Time frame: Baseline, Day 60

  4. Cohort 1 and Cohort 2: Change From Baseline Through Month 60 in North Star Assessment for Limb-girdle Muscular Dystrophies (NSAD) Total Score

    Time frame: Baseline through Month 60

  5. Cohort 1 and Cohort 2: Change From Baseline Through Month 60 in Performance of Upper Limb Version 2.0 (PUL 2.0) Total Score

    Time frame: Baseline through Month 60

  6. Cohort 1: Change From Baseline Through Month 60 in the Time to Rise from the Floor Test

    Time frame: Baseline through Month 60

  7. Cohort 1: Change From Baseline Through Month 60 in the Time to Complete the 10-meter Walk/Run (10MWR) Test

    Time frame: Baseline through Month 60

  8. Cohort 1: Change From Baseline Through Month 60 in the Time to Ascend 4 Steps Test

    Time frame: Baseline through Month 60

  9. Cohort 1: Change From Baseline Through Month 60 in the Time to Complete the 100-meter Walk/Run (100MWR) Test

    Time frame: Baseline through Month 60

  10. Cohort 1: Change From Baseline Through Month 60 in the Timed Up and Go Test

    Time frame: Baseline through Month 60

  11. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (SAEs) and Adverse Events of Special Interests (AESIs)

    Time frame: Baseline through Month 60

  12. Change From Baseline Through Month 60 in Creatine Kinase Level

    Time frame: Baseline through Month 60

  13. Time to Change of Loss of Ambulation

    Time frame: Baseline through Month 60

07

Study locations

10 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Mar 2025, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2024
First posted
Feb 7, 2024
StartActual
Jan 15, 2024
Primary completionActual
Mar 4, 2025
CompletionEst.
Nov 30, 2029
Results delay requested
Feb 27, 2026
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06246513
Responsible party
Sponsor
First posted
Feb 7, 2024
Start date
Jan 15, 2024
Primary completion
Mar 4, 2025
Completion
Nov 30, 2029 (estimated)
Last update
Mar 2, 2026

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion